These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 36690455)

  • 1. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
    Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
    Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
    Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
    Redenbaugh V; Chia NH; Cacciaguerra L; McCombe JA; Tillema JM; Chen JJ; Lopez Chiriboga AS; Sechi E; Hacohen Y; Pittock SJ; Flanagan EP
    Mult Scler; 2023 Jun; 29(7):799-808. PubMed ID: 37218499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Cacciaguerra L; Abdel-Mannan O; Champsas D; Mankad K; Krecke KN; Chen JJ; Syc-Mazurek SB; Redenbaugh V; Lopez-Chiriboga AS; Valencia-Sanchez C; Hemingway C; Tillema JM; Ciccarelli O; Pittock SJ; Hacohen Y; Flanagan EP
    Neurology; 2024 May; 102(10):e209303. PubMed ID: 38710000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
    Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
    Chia NH; Redenbaugh V; Chen JJ; Pittock SJ; Flanagan EP
    Mult Scler; 2023 May; 29(6):748-752. PubMed ID: 36691800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
    Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Cortese R; Prados Carrasco F; Tur C; Bianchi A; Brownlee W; De Angelis F; De La Paz I; Grussu F; Haider L; Jacob A; Kanber B; Magnollay L; Nicholas RS; Trip A; Yiannakas M; Toosy AT; Hacohen Y; Barkhof F; Ciccarelli O
    Neurology; 2023 Jan; 100(3):e308-e323. PubMed ID: 36192175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Cortese R; Battaglini M; Prados F; Gentile G; Luchetti L; Bianchi A; Haider L; Jacob A; Palace J; Messina S; Paul F; Marignier R; Durand-Dubief F; de Medeiros Rimkus C; Apostolos Pereira SL; Sato DK; Filippi M; Rocca MA; Cacciaguerra L; Rovira À; Sastre-Garriga J; Arrambide G; Liu Y; Duan Y; Gasperini C; Tortorella C; Ruggieri S; Amato MP; Ulivelli M; Groppa S; Grothe M; Llufriu S; Sepulveda M; Lukas C; Bellenberg B; Schneider R; Sowa P; Celius EG; Pröbstel AK; Granziera C; Yaldizli Ö; Müller J; Stankoff B; Bodini B; Barkhof F; Ciccarelli O; De Stefano N;
    Ann Neurol; 2024 Aug; 96(2):276-288. PubMed ID: 38780377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
    Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
    Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
    Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
    Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.